Showing results (2141-2150 of 2,436) with videos related to

Sort By:
Pageof 244
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
Science (New York, N.Y.)|February 6, 2025
The Silene latifolia genome and its giant Y chromosomeCarol Moraga, Catarina Branco, Quentin Rougemont, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 7, 2021
Biallelic variants in TMEM222 cause a new autosomal recessive neurodevelopmental disorderDaniel L Polla, Mohammad Ali Farazi Fard, Zahra Tabatabaei, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
American Journal of Human Genetics|November 6, 2020
NCKAP1 Disruptive Variants Lead to a Neurodevelopmental Disorder with Core Features of AutismHui Guo, Qiumeng Zhang, Rujia Dai, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Scientific Reports|February 14, 2025
Investigating the presence of different bottlenose dolphin ecotypes in the Mediterranean SeaMichela Bellingeri, Alice Nebuloni, Gabriella La Manna, et al.
Eclinicalmedicine|July 12, 2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyMelissa Bersanelli, Elena Verzoni, Alessio Cortellini, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Pageof 244